Cytokinetics director receives stock and option grant

Cytokinetics director B. Lynne Parshall received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cytokinetics director B. Lynne Parshall received new equity awards. On 2026-05-27, she was granted 2,851 shares of Cytokinetics common stock at no cost, increasing her direct holdings to 20,784 shares.

She was also granted a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share, expiring on 2036-05-26. These awards are compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 7,152 shares

Grant/Award 2 txns

Insider PARSHALL B LYNNE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	$0.00
Grant/Award	Common Stock	2,851	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 contracts (Direct); Common Stock — 20,784 shares (Direct)

Key Figures

Common stock grant: 2,851 shares Shares held after grant: 20,784 shares Option grant size: 4,301 shares +2 more

5 metrics

Common stock grant 2,851 shares Awarded on 2026-05-27 at $0.00 per share

Shares held after grant 20,784 shares Director’s direct common stock holdings post-transaction

Option grant size 4,301 shares Non-qualified stock option covering common stock

Option exercise price $77.15 per share Conversion or exercise price for the option

Option expiration 2036-05-26 Expiration date of the non-qualified stock option

Key Terms

Non-Qualified Stock Option (Right to Buy), grant/award acquisition, Form 4, exercise price

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

exercise price financial

"conversion_or_exercise_price: "77.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYTK director B. Lynne Parshall report in this Form 4?

Director B. Lynne Parshall reported receiving equity awards in Cytokinetics common stock. She was granted 2,851 shares at no cost and a non-qualified stock option for 4,301 shares, reflecting compensation rather than open-market trading activity.

How many CYTK common shares does B. Lynne Parshall hold after this grant?

After the reported grant, B. Lynne Parshall directly holds 20,784 shares of Cytokinetics common stock. This total includes the newly granted 2,851 shares, which were awarded at no cost as part of her director compensation.

What are the key terms of the stock options granted to the CYTK director?

The director received a non-qualified stock option covering 4,301 shares of Cytokinetics common stock. The option has an exercise price of $77.15 per share and an expiration date of 2036-05-26, providing long-term potential equity exposure.

Does this CYTK Form 4 show the director buying or selling shares in the market?

The Form 4 does not show open-market buying or selling. Instead, it reports a grant of 2,851 common shares and a non-qualified stock option for 4,301 shares, both received as compensation with no purchase price paid per share.

Is the CYTK director’s option grant linked to any remaining derivative holdings?

This filing shows a newly granted non-qualified stock option for 4,301 shares as of 2026-05-27. The derivative summary does not list additional remaining derivative positions beyond this award in the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/27/2026 - 07:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSHALL B LYNNE

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/27/2026		A		2,851	A	$0	20,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Ms. Parshall	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR